Depurination of Brome mosaic virus RNA3 inhibits its packaging into virus particles

Rajita A. Karran and Katalin A. Hudak*

Department of Biology, York University, Toronto, ON M3J 1P3, Canada

Received September 28, 2010; Revised April 28, 2011; Accepted April 29, 2011

ABSTRACT

Packaging of the segmented RNA genome of Brome mosaic virus (BMV) into discrete particles is an essential step in the virus life cycle; however, questions remain regarding the mechanism of RNA packaging and the degree to which the viral coat protein controls the process. In this study, we used a plant-derived glycosidase, Pokeweed antiviral protein, to remove 14 specific bases from BMV RNA3 to examine the effect of depurination on virus assembly. Depurination of A771 within ORF3 and A1006 in the intergenic region inhibited coat protein binding and prevented RNA3 incorporation into particles. The disruption of interaction was not based on sequence identity, as mutation of these two purines to pyrimidines did not decrease coat protein-binding affinity. Rather, we suggest that base removal results in decreased thermodynamic stability of local RNA structures required for packaging, and that this instability is detected by coat protein. These results describe a new level of discrimination by coat protein, whereby it recognizes damage to specific viral RNA elements in the form of base removal and selects against incorporating the RNA into particles.

INTRODUCTION

Packaging is an essential step in the life cycle of a virus, whereby assembly of viral genomes with virally encoded coat protein (CP) protects the genome from degradation and serves as the primary means for transfer of the virus from one host to the next. For Brome mosaic virus (BMV), a member of the family Bromoviridae, which infects grasses such as barley, the ability to package its viral genome into particles is also essential for cell-to-cell movement and hence systemic infection in plants (1).

The genome of BMV is composed of three single-stranded, positive-sense messenger RNAs and one subgenomic RNA (2,3). RNA1 (3.2 kb) and RNA2 (2.9 kb) are monocistronic and encode the 1a and 2a replicase proteins, respectively (4,5). RNA3 (2.1 kb) is dicistronic, and encodes the 5' -proximal movement protein, which is translated directly from RNA3, and the 3' -proximal CP, which is translated from a subgenomic RNA4 (0.9 kb), synthesized from the 3' open reading frame (ORF) of RNA3 (6). RNA1 and RNA2 are packaged independently into separate virus particles, whereas RNA3 and the subgenomic RNA4 are co-packaged into a third virion (7). Each viral particle is comprised of either RNA1, 2 or 3 and sgRNA4 along with 180 molecules of CP, which together form an icosahedral virion (8). Although other viral and cellular components may assist in the formation of particles in vivo, the ability to reconstitute particles in vitro from only viral RNA and CP indicates that particle assembly relies heavily on interactions between these two components.

Particular regions of RNA3 have been shown to be necessary for packaging. For example, the 3' tRNA-like structure found at the terminus of each BMV RNA is hypothesized to facilitate the pentamer formation of CP dimers, which are the building blocks of the icosahedral particle (9). Because the tRNA-like structure is common to all BMV RNAs and can be functionally replaced by a cellular tRNA, it is not a specific packaging signal for individual RNAs; however, the lack of particle formation in its absence shows the importance of this structure for packaging (10). The fact that viral RNAs are distinguished from cellular RNAs during packaging suggests that sequence- or shape-specific regions of each BMV RNA must exist that are recognized by the CP. A stem-loop region of the movement protein gene of RNA3 has been identified as an RNA element required for efficient packaging, as its deletion substantially diminished particle formation (11,12).

In the current study, we have determined that the CP is selective in packaging of viral RNA, as it is able to distinguish between damaged and intact RNAs. Damage was achieved by depurination, caused by the enzyme activity of Pokeweed antiviral protein (PAP). PAP is a glycosidase that has been shown to remove specific purine bases from RNA3 and to inhibit accumulation of BMV RNAs in
barley protoplasts (13,14). Previously, we mapped these
depurination sites and determined how missing bases
within the intergenic region and at the 3' end of RNA3
inhibited the initiation and elongation steps of replication,
respectively (14). Here, we show that depurination of
particular nucleotides within ORF3 and the intergenic
region of RNA3 prevents incorporation of RNA3 into
particles. Even though CP does not bind to a portion of
RNA3 containing only the intergenic region, we dem-on-
strate that when present, the intergenic region enhances
CP interaction with RNA3 ORF3. In addition to contrib-
uting new information describing how CP recognizes
RNA3, we also illustrate how depurination inhibits for-
mation of particles, thereby extending our knowledge of
the antiviral activity of PAP to the packaging step of the
virus life cycle.

MATERIALS AND METHODS

Isolation and transfection of barley protoplasts

Protoplasts were isolated from 7-day-old barley leaves
by enzymatic digestion as described previously (15). Protoplasts (3 × 10^5) were transfected with capped, in vitro transcripts of BMV RNAs (1.0 µg each) and 25 µg of a PAP cDNA, under the control of a constitutive CaMV promoter, using PEG 1500 as described (13), and incubated at 25°C under constant fluorescent light (165 µmol/m²/s) for 18 h.

Protoplast protein and nucleic acid analyses

Aliquots of protoplasts transfected with BMV RNAs
and PAP cDNA were removed at indicated time points.
Protoplasts were pelleted at 1000 g for 20 s and cells were
lysed by adding 300 µl of extraction buffer (2 × TE, 1% SDS). Total protein was precipitated by adding 1 ml of
100% trichloroacetic acid and the amount of protein
was quantified by Bradford assay. Immunoblotting to
detect PAP and CP expression was performed as described
(16), using PAP and CP polyclonal antibodies at 1:5000.

Virion particle isolation from barley protoplasts

Following transfection and incubation for 18 h, pro-
toplasts were ground in extraction buffer (0.5 M NaH_2PO_4, pH 4.5, 80 mM MgCl_2, 1% β-mercapto-
ethanol). The lysate was then transferred to microcen-trifuge tubes and centrifuged at 5000 g for 15 min at 4°C. The aqueous layer was centrifuged at 17,150 g for 90 min at
4°C through a 10% sucrose cushion. The pellet, contain-
ing virion particles, was resuspended and treated with
1 µg/µl of RNase A for 30 min at 30°C, to remove unen-
capsidated RNAs. Virions were concentrated in a
100-kDa cut-off centrifugal filter and resuspended in
virus buffer (50 mM NaH_2PO_4, pH 4.5, 8 mM MgCl_2).

Infectivity of viral particles

*Chenopodium quinoa* plants were grown to the four-leaf
stage before inoculation with BMV virion isolated from
barley protoplasts. Isolated virions (15 µg) from either
PAP-expressing or wild-type protoplasts were added to
500 µl inoculation buffer (10 mM NaH_2PO_4, 10 mM
MgCl_2, 2% silicon carbide). An aliquot of this mixture
(20 µl) was rubbed onto a second tier leaf of each plant,
and plants were maintained at 25°C/20°C day/night tem-
perature and 16-h day length with 180-µmol/m²/s light
intensity. Plants were monitored for the appearance of
local lesions. Nine days post infection, lesions were
counted and leaves were photographed.
The particles contained within this pellet were used as a source of CP for in vitro assembly of particles, described below.

**CP preparation, virion assembly assays and electron microscopy**

CP was disassembled from isolated BMV particles for in vitro virion assembly assays as described previously (17). Virion assembly reactions were conducted as previously described with minor modifications (18). For each virion assembly reaction, purified BMV CP and wild-type or mutant RNA3 were mixed in a 1:5 (wt/wt) ratio and dialyzed for 24 h at 4°C in assembly buffer (100 μl; 50 mM NaCl, 50 mM Tris–HCl, pH 7.2, 10 mM KCl, 5 mM MgCl2, 1 mM DTT). Following dialysis, assembled particles were isolated by centrifugation at 17,150 g for 90 min at 4°C through a 10% sucrose cushion. The pellet, containing virion particles, was resuspended and treated with 1 μg/ml of RNase A for 30 min at 30°C to remove unencapsidated RNA. Assembled virions were concentrated in a 100-kDa cutoff centrifugal filter and resuspended in virus buffer (50 mM NaH2PO4, pH 4.5, 8 mM MgCl2). In some cases, the RNA3 was treated with PAP prior to assembly, as described previously (14). Assembled particles were negatively stained with 1% uranyl acetate and visualized with a transmission electron microscope (Philips EM210). Percentage value indicates the mean number of particles from PAP-treated RNA3 relative to untreated RNA3 ± SE from five fields of view.

**Virion RNA analysis**

RNA was isolated from virions as described previously (19) and equal volume of RNA was separated in a 7 M urea/4.5% acrylamide gel for northern blot analysis as described above. For primer extension analysis, RNA3 was isolated from gel slices of either total protoplast RNA or total virion RNA separated through 7 M urea/4.5% acrylamide. The extension reaction was performed as described previously (14). For real-time quantitative reverse transcriptase-polymerase chain reaction (RT–PCR and radiolabeled PCR, equal amounts of isolated RNA3 from virions (0.5 μg), along with a positive control depurinated RNA3 (0.5 μg) were reverse-transcribed with SuperScript-II-RT. Quantitative PCR was performed with 200 nM of both sense and antisense primers (5′ GT AAAATACCAACTAATTCTCG 3′; 5′ TGGTCTC TTT TAGAGATTTACAGTG 3′) in a final volume of 25 μl using the SYBR Green PCR core reagent (Invitrogen) in an ABI PRISM 7700 Sequence Detection System Instrument (Applied Biosystems). Known amounts of DNA3 were also amplified to generate a standard curve and the equation \( Y = 29.56 \times 10^{0.0355} \). Quantification of the PCR products was determined using the cycle threshold (Ct) values obtained. Radiolabeled PCR was conducted in the presence of [γ-33P]-dATP (10 mCi/ml; GE Healthcare) using a forward primer that annealed to the first nucleotide of BMV and reverse primer that annealed to the last nucleotide of BMV RNA3, resulting in amplification of a 2113-bp fragment.

**Construction of PAP-resistant cDNA3 mutants and A1006 deletion mutant**

To create PAP-resistant cDNA3, a series of overlapping PCRs was conducted to mutate all the observed depurinated nucleotides in BMV RNA3 from purines to pyrimidines. The mutations, written as nucleotide change and (amino acid change), were as follows: A116T (S to C), A285C (D to A), A342T (D to V), A371C (M to L), A374T (N to Y), A771T (D to V), G901C (E to A), A1006C (V to V), A1008C (N to T), A1219T (R to S), G1225T (M to I), G1544T (V to F), A1953C (D to A), A1971C (K to T). The resulting resistant cDNA3 was cloned into the BamHI and EcoRI sites of pBluescript vector and capped, in vitro transcripts were synthesized. To produce the cDNA3 mutant for which only A771 could be potentially depurinated (R-RNA3 771), the resistant cDNA3 was used as template for overlapping PCR to re-introduce the wild-type A771 in place of the pyrimidine T771 from R-cDNA3. Using the same strategy, the resistant cDNA3 was used as template for overlapping PCR to re-introduce the wild-type A1006 in place of the pyrimidine C1006 from R-cDNA3 to create R-RNA3 1006, and the two nucleotides together were reverted to wild-type to create the mutant R-RNA3 771 1006, which could be depurinated only at A771 and A1006. To produce the cDNA3 mutant that was resistant to depurination only at A771 (RNA3 771-R) or A1006 (RNA31006-R), wild-type cDNA3 was used as template for overlapping PCR to exchange A771 for T771 or A1006 for C1006, respectively. In the same manner, the double mutant resistant to depurination at A771 and A1006 (RNA3 771 1006-R) was created by overlapping PCR to exchange A771 for T771 and A1006 for C1006, using wild-type cDNA3 as template. The deletion mutant missing A1006 (RNA3 Δ1006) was constructed by overlapping PCR using wild-type cDNA3 as template. These mutant constructs were cloned into the BamHI and EcoRI sites of pBluescript vector and capped, in vitro transcripts were synthesized.

**Construction of RNA3 fragments, electrophoretic mobility shift assay and filter binding**

The mutant cDNA3 with all observed depurinated nucleotides changed from purines to pyrimidines, except A771 and A1006 (R-RNA3 771 1006), was used as the template DNA for a series of PCRs to create less than full-length RNA3. A forward primer that annealed at nucleotide 92 and reverse primer that annealed at nucleotide 1246 were used to create a DNA3 fragment encoding RNA3 ORF3 and the intergenic region (ORF3+1GR). A forward primer annealed at nucleotide 92 and reverse primer at nucleotide 1003 were used to produce a DNA3 fragment encoding RNA3 ORF3 only (ORF3 771). A forward primer 1004 and reverse primer 1246 were used to create a DNA3 construct encoding RNA3 intergenic region (1GR). These fragments were cloned into the BamHI and EcoRI sites of pBluescript vector and used as template to transcribe radiolabeled 32P-labeled RNA3 fragments. These in vitro transcripts were treated with PAP or buffer only (14) and used to perform
electrophoretic mobility shift assay (EMSA) and filter-binding analysis with isolated BMV CP. Increasing amounts of CP were incubated with PAP-treated or untreated 32P-labeled RNA3 fragments in binding buffer [50 mM Tris–HCl, pH 7.5, 50 mM NaCl, 4 mM MgCl2, 1 mM DTT, 1 mM ethylenediaminetetraacetic acid (EDTA), 5% glycerol] at room temperature for 30 min. For EMSA, the samples were separated through 6% non-denaturing acrylamide gels, and radiolabel was visualized with a phosphorimager. For filter-binding analysis, the samples were passed through a nitrocellulose filter. The amount of retained, labeled RNA was determined by scintillation counting and corrected by subtracting background counts in the absence of BMV CP. The Kd values were extrapolated after the results were fitted with the one site binding equation using Graphpad Prism 4.0.

Construction of RNA3 fragment and UV melting analysis

A 162-nt fragment of RNA3 containing A771 was created by PCR using a forward primer that annealed at nucleotide 679 and reverse primer that annealed at nucleotide 840 on wild-type cDNA3. The only nucleotide that could be depurinated by PAP within the resulting RNA fragment was A771. A PAP-resistant form of this RNA3 fragment was created by PCR using the same primers but R-cDNA3 as template, in which all observed depurinated purines were exchanged for pyrimidines. The resulting cDNA3 fragment contained the mutation A771T, which could not be depurinated in the RNA transcript. The wild-type and mutant cDNA3 fragments were cloned into the BamHI and EcoRI sites of pBluescript vector and capped, in vitro transcripts were synthesized. The in vitro transcripts were PAP-treated or incubated in buffer alone, as described previously (14). Primer extension confirmed that the fragment was as susceptible to depurination at A771 as full-length RNA3 (data not shown). Transcripts were resuspended in buffer (10 mM Tris–HCl, pH 7.0, 5 mM NaCl) and then heated to 85°C and then cooled on ice prior to melting temperature analysis. The absorbance of the samples was monitored at 260 nm from 25 to 85°C. Data were collected with a rate of change in temperature of 1°C/min using a Beckman-Coulter DU 800 UV/VIS spectrophotometer with a Peltier Temperature Programmer. The first temperature derivatives of the absorbance at 260 nM (dA260/ dT) were plotted against increasing temperature. The maximum point of each plot represents the melting temperature (Tm) of each fragment.

RESULTS

PAP decreases the production of virus from protoplasts

To investigate the effect of PAP on virus packaging, we transfected BMV RNA1, 2 and 3 into barley protoplasts expressing PAP and isolated virus particles from the cells. Transmission electron microscopy indicated no visible difference in morphology of particles isolated from PAP-expressing compared with wild-type protoplasts (Figure 1A). However, fewer particles were isolated from cells expressing PAP (21% relative to −PAP), which was also evident when the same volume of isolated virus was probed by northern blot and less viral RNAs were seen associated with particles from PAP-expressing cells (25% relative to −PAP, compare +PAP with RNase A to −PAP with RNase A; Figure 1B). To ensure that RNA not within particles was excluded from the virion preparation, resuspended particles following centrifugation were treated with RNase A prior to northern blot analysis. The intensities of bands in Figure 1B showed no significant difference between nuclease-treated and −untreated particles, indicating a lack of free unencapsidated RNAs. As a control for RNAse A activity, BMV RNAs isolated from virions were also treated with the nuclease and show complete degradation (absence) of the RNA.

To assess whether this decrease in particle number correlated with less total BMV RNA in PAP-expressing protoplasts, total RNA and virion RNA were isolated from PAP-expressing protoplasts and their levels compared with wild-type cells (Figure 1C). The amount of total BMV RNA in PAP-expressing cells 18 h after transfection was consistently less than cells not expressing PAP, which agrees with our previous results showing that PAP inhibits the replication, and hence accumulation, of BMV RNAs (13). However, the ratio of signal intensities between virion RNA and total BMV RNA indicates that less RNA was packaged relative to the total amount in cells expressing PAP (0.36) compared with wild-type cells (0.61). This difference in ratio suggests that the lack of virion production was not solely due to less viral RNA in PAP-expressing cells, but that a portion of the total BMV RNA was excluded from particles. To confirm the expression of PAP and CP in barley protoplasts, we tested aliquots of cells over time, from co-transfection of the PAP encoding plasmid with the three infectious transcripts of BMV RNA (0 h) to time of harvest (18 h). The overlap in expression pattern of PAP and CP indicates that the protein components required to test the effect of PAP on packaging were present in protoplasts (Figure 1D). Taken together, these data suggest that the lack of virion production in PAP-expressing cells was not due to insufficient total BMV RNA or CP synthesis in protoplasts.

PAP does not alter the quality of virus from protoplasts

To examine the quality of the viral RNA packaged, quantitative PCR was performed using RNA3 from virions as template. The premise of this test is that if the viral RNA were depurinated by PAP, the presence of a missing base would stall the RT and less than full-length cDNA would be produced which would not be amplified in the real-time PCR reaction. A positive control was generated for this assay by using RNA3 incubated with PAP in vitro as template for the RT (Figure 2A, control). The same amount of RNA3 isolated from virions of PAP-expressing and wild-type protoplasts resulted in similar amounts of PCR product, indicating that the quality of the RNA3 within viral particles was not significantly different. The relative quantity was substantially greater than that of RNA3 treated in vitro with PAP (control), suggesting that depurinated RNA3 was not present in virions of
PAP-expressing cells. Results of reverse transcription followed by radiolabeled PCR indicated the same trends; that is, the intensity of PCR products from RNA3 templates isolated from virions of PAP-expressing and wild-type protoplasts was similar and substantially greater than the depurinated control template (Figure 2B). Therefore, PAP does not alter the quality of virus from protoplasts. Barley protoplasts were transfected with a plasmid encoding the PAP gene (+PAP) or empty plasmid (–PAP), plus BMV RNA1, 2 and 3 \textit{in vitro} transcripts and incubated for 18 h. Virion particles were isolated from cells and BMV RNAs associated with particles were separated through 7M urea/4.5% acrylamide gel. Gel purified RNA3 (0.5 µg) was reverse transcribed (RT) and used for quantitative PCR (A) and radioactive PCR (B). Quantitative PCR results are plotted as microgram amount of DNA product. The control lane represents \textit{in vitro} PAP-treated RNA3 used for RT–PCR. Values of radioactive PCR are means of intensities for RNA3 ± SE for three separate experiments. (C) Virion particles were isolated from PAP-expressing and wild-type protoplasts and equal amounts (15 µg) were used to infect Chenopodium quinoa plants. Infectivity of viral particles was assessed by counting the number of lesions, 9 days post infection. Percentage value indicates the mean number of lesions on leaves of plants infected with particles taken from PAP-expressing barley protoplasts (+PAP), relative to particles isolated from wild-type protoplasts (–PAP) ± SE from five leaves.
the radioactive PCR method was used in future experiments to examine the quality of the packaged RNA3. Equal amounts of virions from PAP-expressing and wild-type protoplasts were used to infect *C. quinoa* plants, a local lesion host of BMV, to determine whether the two virus preparations were equally infectious. Nine days following infection, the number of lesions was counted and no significant difference existed between particles isolated from PAP-expressing protoplasts compared with wild-type protoplasts (104% ± 7; Figure 2C). Taken together, these data suggest that PAP expression in barley protoplasts does not alter the quality of viral particles synthesized but reduces the number of particles formed.

PAP depurinates BMV RNA3 *in vivo*

To investigate how PAP expression may be limiting particle formation, we first tested for the presence of depurinated viral RNA in cells. Total RNA from wild-type and PAP-expressing protoplasts transfected with BMV RNA1, 2 and 3 was isolated and RNA3 analyzed by primer extension. Ten primers specific to RNA3 were extended and 14 depurinated nucleotides were identified along its length. Their relative location and nucleotide numbers are outlined in Figure 3A with examples of specific sites (Figure 3B). These same depurinated nucleotides were identified previously by *in vitro* incubation of RNA3 with PAP (14). Therefore, the depurination pattern of RNA3 seen *in vivo* from PAP-expressing cells was the same as we observed previously for *in vitro* treated RNA3.

**Depurination inhibits packaging of RNA3 *in vitro***

To investigate whether depurination of BMV RNA directly affected packaging, virus particles were assembled using *in vitro* transcript of PAP-treated or untreated BMV RNA3 and CP isolated from virions. Assembled viral particles were examined by transmission electron microscopy and fewer particles were observed from samples containing PAP-treated RNA3 (29% relative to −PAP; Figure 4A). No difference in signal intensity of radiolabeled PCR product was detected for RNA3 from virions formed from PAP-treated or untreated RNA3, indicating that the quality of the RNA3 from assembled particles was the same (Figure 4B). The signal intensity of PCR product from PAP-treated RNA3 (control) was substantially less, as would be expected from depurinated RNA as template. The integrity of RNA3, both before its assembly and 24 h following particle formation, was verified by northern blot analysis and no visible degradation was observed (Figure 4C). These data suggest that depurination by PAP inhibits viral RNA packaging and that CP preferentially selects non-depurinated RNA3.

**Depurination inhibits binding of CP to RNA3***

To test whether CP distinguishes depurinated from intact RNA3, PAP-treated or untreated RNA3 was incubated with isolated CP and interaction was assessed by filter binding. The affinity of CP for PAP-treated RNA3 was ~6-fold less compared with untreated RNA3 (*K*<sub>d</sub> of 2.32 µM versus 0.36 µM; Figure 5A). To verify that inhibition of binding was due to depurination, RNA3 was modified such that all purines susceptible to removal by
PAP were substituted with pyrimidines, thereby making an RNA3 that could not be depurinated by PAP (R-RNA3). No significant difference in binding affinity of CP was observed for PAP-treated compared with untreated resistant RNA3, indicating that depurination inhibited interaction of CP with RNA3 (Figure 5B). In addition, the dissociation constants for untreated wild-type compared with untreated resistant RNA3 were the same, showing that modification of these bases from purines to pyrimidines did not decrease CP binding. The radiolabeled RNAs were subjected to denaturing gel electrophoresis and visualized by phosphorimager before incubation with CP, to ensure that differences in binding affinity were not due to degradation of BMV RNA3 upon PAP treatment (Figure 5C).

Depurination within ORF3 reduces packaging efficiency

Previous work has shown that an ~200-nt region within BMV ORF3, nucleotides 5' 601-817 3', is important for RNA3 packaging (12; boxed in Figure 6A with structural model of stem–loop C included). This region may fold into a structure containing three loops, called stem–loop A, B and C (12). Deletion of stem–loop B and C completely abolished assembly in vitro. PAP depurinates A771 (14) and because this nucleotide is present within stem–loop C, we hypothesized that depurination of A771 might prevent RNA3 packaging into virions. To test this idea, the resistant RNA3 (R-RNA3) was modified to permit depurination at A771 only (R-RNA3 771), and wild-type RNA3 was modified such that A771 was mutated to a pyrimidine, thereby preventing depurination at this nucleotide but still permitting depurination elsewhere in the RNA3 (RNA3 771-R). These four templates, wild-type RNA3, PAP-resistant RNA3 (R-RNA3), PAP-resistant RNA3 except for A771 (R-RNA3 771) and RNA3 resistant only at A771 (RNA3 771-R), were used to assemble particles in vitro. Line drawings of these RNAs are illustrated in Figure 6A. Based on northern blot analysis of RNA3 isolated from an equal volume of virus particles, fewer particles were formed from PAP-treated wild-type RNA3, whereas no difference was observed for R-RNA3, as expected (Figure 6B). Fewer particles were also assembled from RNA3 that was depurinated only at A771 (R-RNA3 771), indicating that this nucleotide is important for packaging. Surprisingly, fewer particles were seen when RNA3 resistant only at A771 (RNA3 771-R) was used for assembly, suggesting that sequences other than A771 also influence packaging.

To identify which nucleotides inhibited packaging when depurinated, apart from A771, primer extension analysis was conducted on PAP-treated RNA3 resistant only at A771 (RNA3 771-R) isolated from assembled particles. All depurinated nucleotides should be detected in particles, except those required for packaging. The nucleotides shown previously to be depurinated by PAP treatment were also depurinated in RNA3 from assembled particles, except A1006 of the intergenic region of RNA3, and A771, even though the source RNA3 was depurinated at A1006 following PAP treatment (right panel control; Figure 6C). The lack of depurination at A771 was expected, given the substitution of this nucleotide to a pyrimidine. However, lack of depurination at A1006 suggests that the intergenic region may be important for packaging, because RNA3 depurinated at this nucleotide was excluded from particles.

Depurination within the intergenic region reduces packaging efficiency

To investigate the possibility that the intergenic region is involved in packaging, RNA3 that permitted depurination only at A1006 (R-RNA3 1006) was incubated with PAP or untreated and used as template for in vitro particle assembly. Less RNA3 from PAP-treated template was isolated from the same volume of particles, suggesting that depurination only within the intergenic region inhibited packaging of RNA3 (Figure 7A, lanes 3 and 4). Therefore, both ORF3 A771 (Figure 7A, lanes 1 and 2) and intergenic region A1006 are independently critical for packaging of BMV RNA3 into virions. We hypothesized...
that if both these nucleotides are required, then an RNA3 that cannot be depurinated at both A771 and A1006, but retains its ability to be depurinated elsewhere, should allow all of the RNA3 to be packaged, even the depurinated strands. This mutant was synthesized (RNA3 771 1006-R), incubated with PAP and used as template for virion assembly. The amount of RNA3 isolated from virions assembled from PAP-treated compared with untreated RNA3 was similar (Figure 7A, lanes 5 and 6). Therefore, depurination of nucleotides apart from A771 and A1006 did not prevent packaging, i.e. depurinated RNA3 was packaged into particles provided that bases of A771 and A1006 were not removed. Depurination of only A771 and A1006 resulted in less RNA3 assembled, as expected (Figure 7A, lanes 7 and 8) and was similar to PAP-treated or untreated wild-type RNA3 (Figure 7A, lanes 9 and 10), indicating that RNA3 depurinated at A771 and A1006 was excluded from particles.

To test if depurinated RNA3 was present within virion particles assembled from the mutant that did not permit depurination of A771 and A1006 (RNA3 771 1006-R), reverse transcription followed by radioactive PCR was conducted on equal amounts of RNA3 isolated from particles. Substantially less PCR product was visualized from PAP-treated RNA3 compared with untreated RNA3, indicating that damaged RNA3 was packaged into virions assembled from the transcript that could not be depurinated at nucleotides A771 and A1006, but could be depurinated elsewhere (Figure 7B, lanes 5 and 6). As expected, an equal amount of PCR product was observed from RNA isolated from virions made from wild-type RNA3 or RNA3 resistant to depurination (R-RNA3) treated with PAP, as RNA3 depurinated at either nucleotide would not be packaged into particles. These data confirm that nucleotides A771 and A1006 are

Figure 5. Depurination inhibits binding of CP to RNA3. (A) Binding curves of CP with PAP-treated and untreated radiolabeled wild-type BMV RNA3 and (B) PAP-resistant RNA3 (R-RNA3). Transcripts were incubated with increasing concentrations of BMV CP before passing through a nitrocellulose membrane. The amount of retained RNA3 was quantified by scintillation counting and corrected by subtracting background counts in the absence of CP. Points are means ± SE for three separate experiments. The Kd values were obtained after results were fitted to the one site binding equation using Graphpad Prism 4. (C) Radiolabeled wild-type RNA3 (RNA3) and RNA3 resistant to depurination (R-RNA3) were treated with PAP (+PAP) or buffer alone (−PAP). The RNAs were separated through 7 M urea/6% acrylamide gel and visualized with a phosphorimager prior to incubation with CP.
Figure 6. Depurination of A771 inhibits packaging of RNA3. RNA3 constructs were created by site-directed mutagenesis: one that cannot be depurinated by PAP (R-RNA3), one that can be depurinated by PAP only at nucleotide A771 (R-RNA3 771), and RNA3 that cannot be depurinated at A771 only but can be depurinated at other sites (RNA3 771-R). (A) Schematics indicating the sites of depurination for wild-type RNA3, R-RNA3, R-RNA3 771 and RNA3 771-R. An ~200-nt region of RNA3 is boxed and the modeled secondary structure of a portion containing A771 is shown above. (B) Wt RNA3, R-RNA3 771, RNA3 771-R and R-RNA3 were treated with either PAP or buffer only and used for in vitro particle assembly assays with isolated CP. Viral RNA3 was isolated from equal volume of assembled particles and analyzed by northern blot for the presence of positive-strand BMV RNA3. Values are means of intensities for RNA3 ± SE for three separate experiments. (C) Primer extension analysis of RNA3 771-R isolated from virions. cDNA primers distributed over the length of the viral RNA3 were annealed and extended with reverse transcriptase. Radiolabeled cDNA products were separated in a 7 M urea/6% acrylamide gel and visualized with a phosphorimager. The control lane on the right panel represents PAP-treated RNA3 771-R transcript prior to virion assembly, and on the left panel control represents wild-type RNA3 treated with PAP, to illustrate the location of A771 depurination. The bases depurinated by PAP are indicated with arrows and nucleotide numbers. Deoxynucleotide sequencing of BMV DNA3 was conducted using the same primers to identify the depurination sites.
essential for RNA3 packaging and damage to either or both inhibits virion assembly.

We were interested to determine whether deletion of one of these important nucleotides altered the efficiency of RNA3 packaging. We deleted A1006 from the cDNA of RNA3 and the resulting mutant transcript was used for in vitro particle assembly. Northern blot analysis of RNA isolated from the same volume of particles indicated that RNA3 ΔA1006 packaged as well as wild-type RNA3 (Figure 7C). Moreover, PAP treatment of the mutant prior to assembly reduced the total amount of RNA3 packaged, indicating that depurination of A771 still prevented packaging (confirmed by primer extension, data not shown). Therefore, the effect on packaging of deleting one of these nucleotides did not mimic depurination of the same nucleotide.

### CP interaction with RNA3 depurinated at A771 and A1006

Filter-binding analysis was used to test whether the exclusion from particles of RNA3 depurinated at A771 or A1006 was due to decrease in CP affinity for these RNA molecules. CP bound significantly less to RNA3 depurinated only at A771 (R-RNA3 771) compared with non-depurinated RNA3 (K_d of 2.50 μM versus 0.23 μM; Table 1). PAP treatment of RNA3 resistant to depurination except at A1006 (R-RNA3 1006) also significantly reduced the affinity of CP; the dissociation constant for untreated RNA3 was 0.30 μM compared with 2.63 μM for PAP-treated RNA3. Finally, CP bound to RNA3 depurinated only at A771 and A1006 (R-RNA3 771 1006) with similar affinity as depurinated wild-type RNA3 (K_d of 2.89 μM versus 2.32 μM; Table 1 and Figure 5A). Therefore, A771 and A1006 are important for efficient CP binding to RNA3.

BMV CP binds to the 3’-UTR of all BMV RNAs (17,20). To determine whether CP could bind to RNA3 containing only ORF3 and the intergenic region, and if depurination at nucleotides A771 and A1006 affected binding, RNA3 fragments were constructed from nucleotides 92–1246 (ORF3+IGR), containing both A771 and A1006; RNA3 from nucleotides 92–1003 (ORF3), containing A771; and RNA3 from nucleotides 1004–1246 (IGR), containing A1006 (Figure 8A). These three constructs were designed to be resistant to depurination except for A771 and A1006 and the affinity of CP for these transcripts was analyzed by filter binding. CP bound less to the ORF3+IGR fragment relative to full-length RNA3; the K_d for ORF3+IGR fragment was 0.94 μM compared with K_d of 0.36 μM for full-length RNA3 (Figure 8A and 5A), which is consistent with the results of Yi et al., (17) indicating the importance of the 3’ end in binding. Our results do not preclude the possibility that CP binds to ORF4, we did not test this. However, depurination at A771 and A1006 substantially reduced

### Table 1: Coat protein affinity for RNA3 depurinated at specific nucleotides, as measured by filter-binding assay

| RNA3 Mutant | K_d μM  |
|-------------|---------|
|             | +PAP    | −PAP   |
| R-RNA3 771  | 2.50    | 0.23   |
| R-RNA3 1006 | 2.63    | 0.30   |
| R-RNA3 771 1006 | 2.89 | 0.20   |
CP binding to ORF3 + IGR ($K_d$ of 7.48 µM), suggesting that this fragment does contain a binding site. CP binding to the ORF3 fragment, in the absence of PAP treatment, was substantially less than ORF3 + IGR, indicating that the intergenic region contributed to binding of CP to ORF3 ($K_d$ of 3.07 µM for ORF3 compared to 0.94 µM for ORF3 + IGR). PAP treatment of ORF3 inhibited binding, indicating that this region has a CP-binding site that is disrupted by depurination at A771. The CP bound with low affinity to the intergenic region, suggesting that this fragment does not contain a CP-binding site. Moreover, PAP treatment did not alter binding (7.18 µM compared with 6.29 µM); therefore, depurination at A1006 does not affect CP binding to the intergenic region alone. Taken together, these data show that fragments of RNA3 in addition to the 3' end are important for CP binding. Moreover, the intergenic region contributes to the binding of CP to ORF3, even though CP does not appear to bind to the intergenic region alone.

To further illustrate that ORF3 has a CP-binding site and that the intergenic region does not, EMSA was conducted with isolated CP and the same fragments, ORF3 + IGR, ORF3 and IGR from R-RNA3 771 1006. CP caused a shift in ORF3 + IGR and a partial shift for ORF3 and no shift for IGR, indicating that the binding of CP to movement protein ORF is enhanced by the presence of IGR, even though CP does not bind to IGR alone (Figure 8B). No shift was observed following PAP treatment of ORF3 + IGR and ORF3, indicating that depurination of A771 and A1006 abolished binding of CP to these fragments.

**Thermal stability of RNA3 fragment depurinated at A771**

We hypothesized that the difference in binding affinity of CP for depurinated compared with non-depurinated RNA was due to decrease in stability of the local RNA structure. To test this possibility, a 162-nt fragment of RNA3 (nt 679–840) containing A771 was treated with PAP or buffer alone, and its thermal stability measured by UV spectrophotometry. Depurination of the RNA fragment at A771 was confirmed by primer extension (data not shown). The average melting temperature of the depurinated RNA3 fragment was 57.6°C (long broken line) compared with the non-depurinated fragment at 62.5°C (solid line; Figure 9). Interestingly, the melting temperature of the RNA fragment in which A771 was mutated to T771 was the same as wild-type, at 62.5°C (short broken line). Therefore, substitution of the purine for a pyrimidine did not alter the overall thermal stability of the RNA fragment. The lower melting temperature of depurinated RNA indicates a higher thermal instability and flexibility relative to both non-depurinated and mutated RNA.

**RNA3 depurinated at A771 and A1006 is not packaged**

To determine whether depurination at nucleotides A771 and A1006 was also critical for RNA3 packaging in vivo, the RNA3 mutants tested for in vitro assembly were transfected, along with wild-type RNA1 and 2, into barley

![Figure 8](image127x192 to 264x260)

**Figure 8.** CP interaction with RNA3 fragments depurinated at A771 and A1006. (A) Schematics showing regions of RNA3 (R-RNA3 771 1006, depurinated only at A771 and A1006) tested for their binding affinity to isolated CP by filter binding assay and EMSA. RNA3 fragments were treated with PAP or buffer only and incubated with increasing concentration of BMV CP before passing through a nitrocellulose membrane. The amount of retained RNA was quantified by scintillation counting and corrected by subtracting background counts in the absence of CP. The $K_d$ values were obtained after results were fitted to the one site binding equation using Graphpad Prism 4, and appear in the table to the right. (B) Radiolabeled RNA3 fragments were incubated with PAP or buffer only, followed by incubation with BMV CP. Samples were separated through a 6% acrylamide non-denaturing gel and the bands were visualized using a phosphorimager.

![Figure 9](image56x746)

**Figure 9.** Thermal stability of RNA3 fragment depurinated at A771. The 162-nt cDNA constructs of RNA3 containing either A771 (wt cDNA3 fragment) or this nucleotide mutated to T771 (R-cDNA3 fragment) were produced by PCR. In vitro transcripts of these cDNAs were treated with PAP or buffer alone. The melting temperatures of the RNA fragments were measured by UV spectrophotometry. The first derivative of the absorbance at 260 nm was plotted as a function of temperature. Wild-type RNA3 fragment is represented by a continuous line, PAP-treated wild-type RNA3 fragment by long broken lines and R-RNA3 fragment by short broken lines. The absorbance of each fragment was measured independently and values are means of each ± SE for three separate experiments.
protoplasts expressing PAP. Assessment by radiolabeled PCR of the quality of the RNA packaged indicated that RNA3 depurinated at only A771 or A1006 was excluded from particles, given that a similar amount of PCR product was observed from equal amount of virion RNA3 template from PAP-expressing and wild-type protoplasts (Figure 10A). In contrast, RNA3 that was resistant to depurination at A771 and A1006 but could be depurinated elsewhere (RNA3 771 1006-R) was incorporated into particles, as seen by the decreased amount of PCR product, indicative of incomplete reverse transcription due to damaged RNA3 in viral particles from PAP-expressing protoplasts. To test whether the lack of incorporation of RNA3 depurinated at A771 or A1006 was due to insufficient depurinated RNA3 in cells, total RNA3 from protoplasts was extracted and the level of depurination estimated by reverse transcription. Radiolabeled cDNA products were extended using a primer that annealed to the 3’-end of RNA3, and depurination resulted in fragments of expected sizes that were less than full-length RNA3. The intensities of bands representing depurination at A771 (for R-RNA3 771), depurination at A1006 (R-RNA3 1006) and depurination at A1971 (the most 3’ depurinated nucleotide for RNA3 771 1006-R and wt RNA3) were plotted relative to total RNA3 (Figure 10B). Approximately 70% of each mutant RNA3 was depurinated, suggesting that lack of depurinated RNA3 in particles containing R-RNA3 771 or R-RNA3 1006 was not due to lack of depurinated template inside cells.

**DISCUSSION**

We observed that PAP expression inhibits the production of virion particles in barley protoplasts transfected with BMV RNAs. Fewer virus particles were formed in PAP-expressing cells; however, their quality and infectivity were not reduced. A decrease in number was also observed when particles were assembled in vitro from isolated CP and PAP-treated RNA3 transcript, suggesting that PAP decreased the fitness of the RNA for packaging. Examination of RNA3 from particles revealed that of the 14 possible depurinated nucleotides, only depurination of A771 in ORF3 and A1006 in the intergenic region prevented incorporation of the RNA. Some specific interactions between CP and RNA3 appear to regulate packaging. Initial competition experiments between BMV RNA, yeast tRNA and Alfalfa mosaic virus RNA resulted in the preferential packaging of BMV RNAs by BMV CP (21). It has been shown since that a 187-nt fragment of the ORF3 of RNA3 is a specific recognition element for the CP (12). Deletion of this fragment from RNA3 resulted in a mutant that was not packaged. We have identified a single nucleotide within this region, A771, which when depurinated, inhibits binding of CP to RNA3. CP detects damage to this nucleotide and does not efficiently package the depurinated RNA3. We suggest that A771, along with A1006 of the intergenic region, are located within RNA elements that impart specificity during initial recognition by the CP.

Deletion mutations within RNA3 have shown that complete removal of the intergenic region did not negatively affect packaging (12). We have observed the same result (data not shown); however, depurination of A1006 within this region inhibited CP binding and excluded the RNA from packaging. Even though packaging occurs in vitro in the absence of the intergenic region, perhaps when present, this intergenic structure regulates the specific interaction of CP with the region of ORF3 containing A771. We have noted previously an unexpected role for the intergenic region in viral replication; namely, that replicase binding to the intergenic region is required for initiation of negative strand synthesis, even though this region is distant from the 3’ terminal core promoter for the replicase. Depurination of A1006 prevented replicase binding to RNA3 and initiation of RNA synthesis (14).
CP also co-purifies with active replicase complex (22) and the replicase has been shown to play a role in assembly as a specificity filter, blocking cellular mRNA packaging into particles (23). Taken together, we speculate that in vivo, the CP associates with the replicase at the intergenic region, and that this complex distinguishes viral RNAs. In vitro, in the absence of replicase, CP can still recognize damage to the intergenic region and will not bind. However, if the IGR is removed, CP looses this form of regulation and binding is achieved by interaction with the specific site within ORF3 containing A771. The existence of two distant regions that bind CP suggests that the tertiary structure of the viral RNA contributes to specificity.

We have shown here that CP can distinguish between damaged RNA3, in the form of depurination at particular sites, and intact RNA3. It was of interest to us that this distinction does not rely on the identity of individual nucleotides because mutation of A771 and A1006 to pyrimidines did not decrease CP binding. Secondary structure predictions based on M-fold analysis indicated that in wild-type RNA3, A771 and A1006 are within loop regions and their mutation to pyrimidines would likely create stem regions that incorporate these nucleotides. The potential establishment of base-pairing and the resulting change in shape of the RNA were also not sufficient to affect CP binding. We hypothesize that the fundamental difference between an intact nucleotide, regardless of identity, and an abasic nucleotide is stability. Overlap between pi orbitals of bases in single-stranded RNA provides substantial stability to the molecule (24,25). Depurination of a nucleotide will disorder the local structure and increase its flexibility due to disruption of base-stacking from the missing purine. We tested this assertion by measuring the melting temperature of a fragment of RNA3 that was depurinated at A771. The melting temperature of the depurinated fragment was consistently lower than the intact fragment. The increased flexibility of a depurinated RNA may mean that recognition structures are not always accessible for CP binding. Therefore, we suggest that this instability is detected by CP, given that its affinity for depurinated nucleotides within these RNA packaging signals was significantly reduced. Interestingly, no difference in melting temperature was detected between the intact wild-type fragment and the same fragment for which the purine was mutated to a pyrimidine. CP also bound with the same affinity to a fragment of RNA3 that was depurinated at A771. The existence of these two nucleotides results in localized instability of the RNA molecule, which is detected by CP and rejected for incorporation into particles. Future work will focus on the role of the replicase, together with CP for packaging in vivo and will identify whether a structural connection between A771 of ORF3 and A1006 of the intergenic region exists to facilitate RNA3 packaging.

ACKNOWLEDGEMENTS

We thank Dr. Cheng Kao for the vectors pB3TP8 bearing BMV DNA3 and pB3HE1 containing a fragment of the tRNA-like structure from the 5′-end of BMV RNA3. We are grateful to Ms. Karen Rethoret for assistance with electron microscopy of virus particles.

FUNDING

A Discovery Grant from the Natural Sciences and Engineering Research Council of Canada; a Premier’s Research Excellence Award; and infrastructural support by the Canada Foundation for Innovation (CFI) and the Ontario Innovation Trust (OIT) (to K.A.H.). Funding for open access charges: Natural Sciences and Engineering Research Council of Canada.

Conflict of interest statement. None declared.

REFERENCES

1. Schmitz,I. and Rao,A.L. (1996) Molecular studies on bromovirus capsid protein. I. Characterization of cell-to-cell movement-defective RNA3 variants of brome mosaic virus. *Virology*, 226, 281–293.
2. Goldbach,R., LeGall,O. and Wellink,J. (1991) Alpha-like viruses in plants. *Semini. Virol.*, 2, 19–25.
3. Ahlquist,P. (1992) Bromovirus RNA replication and transcription. *Curr. Opin. Genet. Dev.*, 2, 71–76.
4. Ahol,T., den Boon,J.A. and Ahlquist,P. (2000) Helicase and capping enzyme active site mutations in brome mosaic virus protein la cause defects in template recruitment, negative-strand RNA synthesis, and viral RNA capping. *J. Virol.*, 74, 8803–8811.
5. Kao,C.C., Quadt,R., Hershberger,R.P. and Ahlquist,P. (1992) Brome mosaic virus RNA replication proteins 1a and 2a from a complex in vitro. *J. Virol.*, 66, 6522–6529.
6. Miller,W.A., Dreher,T.W. and Hall,T.C. (1985) Synthesis of brome mosaic virus subgenomic RNA in vitro by internal initiation on (+)-sense genomic RNA. *Nature*, 313, 68–70.
7. Rao,A.L. (2000) Bromoviruses. In Maloy,O.C. and Murray,T.D. (eds), *Encyclopedia of Plant Pathology*, Wiley, New York, NY, pp. 155–158.
8. Kao,C.C. and Sivakumaran,K. (2000) Brome mosaic virus, good for an RNA virologist's basic needs. *Mol. Plant Pathol.*, 1, 91–97.
9. Zlotnick,A., Aldrich,R., Johnson,J.M., Ceres,P. and Young,M.J. (2000) Mechanism of capsid assembly for anicosahedral plant virus. *Virology*, 277, 450–456.
10. Choi,Y.G., Dreher,T.W. and Rao,A.L. (2002) tRNA elements mediate the assembly of an icosahedral RNA virus. *Proc. Natl Acad. Sci. USA*, 99, 655–660.
11. Dumayami,T.T., Tsukaguchi,S., Mise,K. and Okuno,T. (2003) cis-acting elements required for efficient packaging of brome viral RNA.
12. Choi, Y.G. and Rao, A.L. (2003) Packaging of brome mosaic virus RNA3 is mediated through a bipartite signal. *J. Virol.*, 77, 9750–9757.
13. Picard, D., Kao, C.C. and Hudak, K.A. (2005) Pokeweed antiviral protein inhibits brome mosaic virus replication in plant cells. *J. Biol. Chem.*, 280, 20070–20077.
14. Karran, R.A. and Hudak, K.A. (2008) Depurination within the intergenic region of Brome mosaic virus RNA3 inhibits viral replication in vitro and in vivo. *Nucleic Acids Res.*, 36, 7230–7239.
15. Kroner, P., Richards, D., Traynor, P. and Ahlquist, P. (1989) Defined mutations in a small region of the brome mosaic virus 2 gene cause diverse temperature-sensitive RNA replication phenotypes. *J. Virol.*, 63, 5302–5309.
16. Tourlakis, M.E., Karran, R., DeSouza, L., Siu, K.W.M. and Hudak, K.A. (2010) Homodimerization of pokeweed antiviral protein as a mechanism to limit depurination of pokeweed ribosomes. *Mol. Plant Pathol.*, 11, 757–767.
17. Yi, G., Vaughan, R.C., Yarbrough, I., Dharmiaah, S. and Kao, C.C. (2009) RNA binding by the brome mosaic virus capsid protein and the regulation of viral RNA accumulation. *J. Mol. Biol.*, 391, 314–326.
18. Choi, Y.G. and Rao, A.L.N. (2000) Molecular studies on bromovirus capsid protein VII. Selective packaging of BMV RNA4 by specific N-terminal arginine residues. *Virology*, 275, 207–217.
19. Rao, A.L.N., Duggal, R., Lahser, F.C. and Hall, T.C. (1994) Analysis of RNA replication in plant viruses. In Adolph, K.W. (ed.), *Methods in Molecular Genetics: Molecular Virology Techniques, Part A*, Vol. 4. Academic Press, San Diego, CA, pp. 216–236.
20. Zhu, J., Gopinath, K., Murali, A., Yi, G., Hayward, S.D., Zhu, H. and Kao, C. (2007) RNA-binding proteins that inhibit RNA virus infection. *Proc. Natl Acad. Sci. USA*, 104, 3129–3134.
21. Cuiller, M., Herzog, M. and Hirth, L. (1979) Specificity of in vitro reconstitution of bromegrass mosaic virus. *Virology*, 95, 146–153.
22. Bujarski, J.J., Hardy, S.F., Miller, W.A. and Hall, T.C. (1982) Use of dodecyl-beta-D-maltoside in the purification and stabilization of RNA polymerase from brome mosaic virus-infected barley. *Virology*, 119, 465–473.
23. Annamalai, P. and Rao, A.L. (2005) Replication-independent expression of genome components and capsid protein of brome mosaic virus in planta: a functional role for viral replicase in RNA packaging. *Virology*, 338, 96–111.
24. Sponer, J., Riley, K.E. and Hobza, P. (2008) Nature and magnitude of aromatic stacking of nucleic acid bases. *Phys. Chem. Chem. Phys.*, 10, 2595–2610.
25. Freier, S.M., Petersheim, M., Hickey, D.R. and Turner, D.H. (1984) Thermodynamic studies of RNA stability. *J. Biomol Struct. Dyn.*, 1, 1229–1242.